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S U M M A R Y
Objective: To examine the efﬁcacy of third-line Helicobacter pylori eradication therapy with
esomeprazole, amoxicillin, and sitaﬂoxacin for patients with clarithromycin- and metronidazole-based
ﬁrst- and second-line therapy failure.
Methods: Thirty patients with ﬁrst- and second-line H. pylori eradication failure were treated
prospectively with esomeprazole 20 mg twice daily, amoxicillin 750 mg twice daily, and sitaﬂoxacin
100 mg twice daily for 7 days. After 8–12 weeks, the outcome of eradication therapy was assessed by 13C-
urea breath test or stool antigen test.
Results: All 30 patients completed the study. Eradication was successful in 25 patients and the
eradication rate was 83% in the intention-to-treat and per-protocol analyses. No speciﬁc or signiﬁcant
adverse events were recorded in the 30 patients. Patient characteristics such as sex, body mass index,
and pepsinogen I/II ratio did not differ between patients who were treated successfully and those who
were not treated successfully.
Conclusions: Third-line H. pylori eradication therapy with esomeprazole, amoxicillin, and sitaﬂoxacin is
as safe and effective as previously reported sitaﬂoxacin-based triple therapy.
 2016 The Author(s). Published by Elsevier Ltd on behalf of International Society for Infectious Diseases.
This is an open access article under the CC BY-NC-ND license (http://creativecommons.org/licenses/by-
nc-nd/4.0/).
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jou r nal h o mep ag e: w ww .e lsev ier . co m / loc ate / i j id1. Introduction
Chronic Helicobacter pylori infection causes various gastrodu-
odenal diseases, including ulcers and malignancies.1–4 Eradica-
tion of H. pylori can prevent or cure these diseases.5–7 In fact, some
studies have shown that H. pylori eradication reduces the
incidence of gastric cancer, suggesting that eradication therapy
could be the primary therapeutic approach for upper gastrointes-
tinal diseases.8–12
Many regimens for H. pylori eradication have been tested since
the discovery of this bacterium. Generally, a proton pump inhibitor
(PPI) and antibiotics are included in the eradication regimen to
suppress gastric acid and to kill the bacteria. Bacterial resistance
to speciﬁc antibiotics signiﬁcantly reduces the efﬁcacy of an
eradication regimen containing the corresponding antibiotics, and
resistance is associated with the consumption of antibiotics, which
is inﬂuenced by socio-economic status and geographic area.2,13,14* Corresponding author. Tel.: +81-3-38155411; fax: +81-3-58008812.
E-mail address: Hiratay-int@h.u-tokyo.ac.jp (Y. Hirata).
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license (http://creativecommons.org/licenses/by-nc-nd/4.0/).In Japan, ﬁrst-line therapy consists of a PPI, amoxicillin (AMX),
and clarithromycin (CLR) for 7 days, which results in an
eradication rate of 60–70% due to widespread CLR-resistant
H. pylori.15 Second-line therapy includes a PPI, AMX, and
metronidazole (MNZ), which has an acceptable eradication rate
of 90%.3 No standard third-line therapy has been established,
although several regimens have been examined prospectively for
their efﬁcacy and adverse events.14 Candidate third-line anti-
biotics include ﬂuoroquinolones, one of which, sitaﬂoxacin (STX),
has shown good ability to kill H. pylori in vitro.16 In prospective
studies, STX-based triple therapy has shown a modest eradication
rate of 70–80%.17–19 Studies of primary resistance against STX
have shown that more than 90% of H. pylori strains are susceptible
to this antibiotic.18–20 However, the in vivo eradication rate of this
third-line therapy has not exceeded 90% in most studies, so there
is still room to improve the STX-based third-line eradication
regimen.21
Therefore, a prospective study of the efﬁcacy of a new third-line
Helicobacter eradication regimen containing esomeprazole, AMX,
and STX was performed. Esomeprazole is a PPI that was approved
by the Ministry of Health, Labor and Welfare of Japan in 2011. It hasociety for Infectious Diseases. This is an open access article under the CC BY-NC-ND
Table 1
Demographic characteristics of the patients and results of the eradication therapy
Characteristics Total (n = 30)
Age, years, mean  SE 51.8  2.5
Sex, male/female 15/15
Diagnosis, ulcer/gastritis 15/15
Previous eradication therapy, second/more 28/2
Body mass index, kg/m2, mean  SE 23.7  0.6
Pepsinogen I/II ratio, mean  SE 3.4  0.3
Eradication result, success/failure 25/5
Eradication rate, % (95% CI) (ITT) 83% (65–94%)
Eradication rate, % (95% CI) (PP) 83% (65–94%)
SE, standard error; CI, conﬁdence interval; ITT, intention-to-treat analysis; PP, per-
protocol analysis.
Table 2
Patient characteristics according to the eradication results
Characteristics Patients treated
successfully
(n = 25)
Patients not treated
successfully (n = 5)
p-Value
Age, years, mean  SE 50.8  0.9 56.8  3.5 0.38
Sex, male/female 14/11 1/4 0.14
Diagnosis, ulcer/gastritis 13/12 2/3 0.51
Previous eradication
therapy, second/more
23/2 5/0 0.51
Body mass index, kg/m2,
mean  SE
23.6  0.6 23.9  2.7 0.84
Pepsinogen I/II ratio,
mean  SE
3.4  0.3 3.4  0.6 0.96
SE, standard error.
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lansoprazole and rabeprazole.22,23 However, its efﬁcacy in third-
line therapy has not been evaluated.
2. Materials and methods
2.1. Subjects
A prospective exploratory study was conducted to evaluate
the efﬁcacy of third-line Helicobacter eradication therapy (UMIN
Clinical Trials Registry ID No. 000007971). Adult patients with a
peptic ulcer or chronic gastritis in whom CLR-based ﬁrst-line and
MNZ-based second-line therapy had failed were invited to join
the study. CLR-based ﬁrst-line therapy consists of a PPI, AMX
(750 mg twice daily), and CLR (200 mg or 400 mg twice daily) for
7 days. MNZ-based second-line therapy consists of a PPI, AMX
(750 mg twice daily), and MNZ (50 mg twice daily) for 7 days.
Patients with major organ dysfunction or a history of allergy to
PPIs, AMX, or STX were excluded. Prior use of esomeprazole was
not excluded. Prior use of STX for third-line eradication was
excluded. Written informed consent was obtained from all
patients. The study protocol was approved by the Institutional
Review Board of the University of Tokyo Hospital (approval No.
P2012006).
2.2. Eradication
Before beginning third-line eradication therapy, height and
weight were recorded, and laboratory tests including liver and
renal function tests and pepsinogen were performed. Patients were
assigned to receive esomeprazole 20 mg twice daily, AMX 750 mg
twice daily, and STX 100 mg twice daily for 7 days. A 7-day
treatment duration was applied in this study based on previous
third-line Helicobacter eradication reports.17–19 Compliance and
adverse events were assessed through interviews. The outcome of
eradication therapy was assessed by 13C-urea breath test or stool
antigen test at 8–12 weeks after completing the antimicrobial
treatment.
2.3. H. pylori strains and microbiological examination
In some cases, H. pylori isolates were obtained from biopsy
specimens at endoscopy and examined for antimicrobial
susceptibility. The minimum inhibitory concentrations (MICs)
for AMX, CLR, MNZ, and STX of each strain were determined
using the agar dilution method. The presence of the gyrA
mutation was also examined by direct sequencing, as described
previously.18,24
2.4. Statistical analysis
Statistical analyses were performed using the Chi-square test,
Student t-test, or Wilcoxon rank sum test, as appropriate. A p-value
of <0.05 was considered statistically signiﬁcant.Table 3
Characteristics of Helicobacter pylori strains isolated from patients before and after thir
Case Before therapy 
MIC (mg/ml) gyrA 
AMX CLR MNZ STX 
EAS017 N/A N/A N/A N/A N/A 
EAS020 0.03 32 64 0.03 Wild 
EAS022 N/A N/A N/A N/A N/A 
EAS025 1.0 32 32 0.12 N87K 
MIC, minimum inhibitory concentration; AMX, amoxicillin; CLR, clarithromycin; MNZ,3. Results
Thirty patients with a history of second-line eradication failure
were enrolled from April 2012 to December 2015. The mean age of
the patients was 51.8  2.5 years, and 15 were male (Table 1). All
30 patients took the full course of medication and underwent a 13C-
urea breath test or stool antigen test. Successful eradication was
achieved in 25 cases, giving an eradication rate of 83% (95%
conﬁdence interval 65–94%) for both the intention-to-treat and
per-protocol analyses.
Diarrhea was the most common adverse event, and was
recorded in ﬁve cases (16.7% of the study cohort). One patient
(3.3%) suffered moderate diarrhea with seven defecations over
2 days, but did not require treatment for the diarrhea. A moderate
skin eruption after therapy (3.3%) was observed in one patient and
a moderate asthma attack during therapy (3.3%) was observed in
another patient; both required speciﬁc medications. Stomatitis
(3.3%) and cystitis (3.3%) were recorded in one patient each, but
resolved without speciﬁc treatment.
In a subgroup analysis, age, sex, gastric diseases, previous third-
line therapy, body mass index, and the pepsinogen I/II ratio did not
differ between patients with successful eradication and those with
eradication failure (Table 2).
Table 3 lists the characteristics of the H. pylori strains isolated
before and after third-line therapy. In case EAS025, the H. pylorid-line therapy
Result After therapy
MIC (mg/ml) gyrA
AMX CLR MNZ STX
Failed 0.03 8 32 0.12 N87K
Successful N/A N/A N/A N/A N/A
Failed 0.03 16 64 0.03 N87K
Successful N/A N/A N/A N/A N/A
 metronidazole; STX, sitaﬂoxacin; N/A, not available.
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0.12 mg/ml with the N87K gyrA mutation before therapy, but this
case was treated successfully with the third-line regimen used.
Conversely, the H. pylori strain with the lowest MICs for AMX and
STX was recovered from case EAS022 after the third-line therapy
failed.
4. Discussion
Sitaﬂoxacin-based H. pylori eradication therapy is often used in
Japan.14 As third-line therapy, eradication rates of 70–78% were
reported in three previous prospective studies.17–19 Furuta et al.
conducted a randomized study with four arms, which showed 84–
91% eradication.25 These third-line therapy regimens with STX
used rabeprazole or lansoprazole as the PPI. In this study, the
efﬁcacy of esomeprazole was examined; this is the latest
conventional PPI approved in Japan, and was used for third-line
H. pylori eradication in combination with AMX and STX. An
eradication rate of 83% was obtained and the adverse events were
not speciﬁc or severe. This efﬁcacy is in line with prior STX-based
third-line regimens with rabeprazole or lansoprazole. Contrary to
expectations, the substitution of esomeprazole for rabeprazole or
lansoprazole did not improve the eradication rate.
Several studies have compared the efﬁcacy of eradication with
different PPIs with the aim of improving the eradication regimen.
McNicholl et al. performed a meta-analysis of randomized control
trials of Helicobacter eradication using esomeprazole, and
reported the superiority of esomeprazole over ﬁrst-generation
PPIs.26 The varying acid-inhibiting potential of PPIs may affect the
eradication efﬁcacy. In other cases, different usage of cytochrome
P450 (CYP), which metabolizes PPIs, as well as its single nucleotide
polymorphism, may affect the results . However, it is not clear
whether differences in the PPI affect third-line eradication therapy.
In a previous study, enhanced bactericidal activity of STX at
near-neutral pH was found.18 In addition, a low pepsinogen I/II
ratio, which indicates advanced atrophy and hypochlorhydria
clinically, was associated with a high eradication efﬁcacy using
STX.18 Therefore, it was hypothesized that STX-based therapy
would be beneﬁcial with sufﬁcient acid suppression. However, this
was not the case with the esomeprazole-based third-line therapy
evaluated in the present study. In this study, the eradication rate
did not reach 90%, and the pepsinogen I/II ratio did not affect the
eradication results. The replacement of esomeprazole with
vonoprazan, a novel potassium-competing acid blocker that has
superior gastric acid control over conventional PPIs,27 may
improve the efﬁcacy of STX-based third-line therapy. It is also
possible that factors other than acid suppression, such as bacterial
resistance, are critical to the eradication outcome.13,14
A breakpoint for STX has not been established, and studies have
used different breakpoints of 0.12 and 1.0 mg/ml.19,20,28 As shown
in Table 3, a strain with 0.12 mg/ml MIC of STX was eradicated
successfully, but eradication was unsuccessful for a strain with a
MIC of less than 0.03 mg/ml. In a previous study on the use of
rabeprazole, STX, and AMX, a strain with a STX MIC of 0.12 mg/ml
was not eradicated, while a strain with a MIC of 0.24 mg/ml was
treated successfully.18 These results indicate the difﬁculty in
interpreting in vitro MIC testing in terms of the results of current
third-line eradication therapy. In this study, H. pylori strains were
isolated from only two patients among the ﬁve with unsuccessful
treatment, because culture was negative in two of the patients and
an endoscopy was not performed in the other patient. In the two
patients with negative culture results, the 13C-urea breath test,
histology, and rapid urease test were all positive, indicating that
the culture test was false-negative. More cases are required to
determine the breakpoint of STX, particularly in third-line
therapy.At the time when this study was performed, no other study
using esomeprazole as third-line therapy with STX had been
reported. Recently, Mori et al. published a randomized study that
compared AMX with MNZ as third-line therapy in combination
with STX.28 In that study, esomeprazole was used as the PPI, and
eradication rates of 81% and 72%, respectively, were obtained with
a 10-day third-line regimen. Although the study contained an
extremely high percentage of STX-resistant H. pylori (57% with a
MIC >1.0 mg/ml) compared to other third-line studies, the
eradication rate in the intention-to-treat analysis was comparable
to that of the 7-day protocol used in the present study. Previously,
Furuta et al. examined the efﬁcacy of 1- and 2-week regimens of
STX-based third-line therapy and found no statistically signiﬁcant
difference between the different treatment durations.25 In
contrast, recent consensus statements developed by the Canadian
Association of Gastroenterology and the Canadian Helicobacter
Study Group strongly recommend a duration of 14 days for all H.
pylori treatments.29 Therefore, the appropriate duration of third-
line eradication regimens, as well as of ﬁrst- and second-line
therapy, may require re-evaluation in Japan.
In conclusion, third-line H. pylori eradication therapy with
esomeprazole gave an eradication rate of 83%, which is comparable
to previous STX-based third-line therapy. This suggests that the
substitution of esomeprazole for reported PPIs could be another
option for third-line H. pylori eradication therapy.
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